Guidance For Expanded EP Catheter Indications Forthcoming From FDA
This article was originally published in The Gray Sheet
Executive Summary
FDA will issue a level-one guidance for PMAs that seek general indications for the treatment of arrhythmias with electrophysiology (EP) catheters.
You may also be interested in...
Regulatory News In Brief
FDA panel appointment: Aradigm VP-Clinical & Regulatory Affairs Babatunde Otulana, MD, joins Anesthesiology & Respiratory Therapy Devices Panel for a four-year, non-voting stint as its industry representative. Otulana, who joined Aradigm in 1997, previously served as a medical reviewer at the Center for Drug Evaluation & Research's pulmonary division. Aradigm's AERx pulmonary drug delivery platform recently completed Phase II studies with Novo Nordisk for an inhaled insulin formulation. A Phase III study could begin in early 2002, firm says...
Regulatory News In Brief
FDA panel appointment: Aradigm VP-Clinical & Regulatory Affairs Babatunde Otulana, MD, joins Anesthesiology & Respiratory Therapy Devices Panel for a four-year, non-voting stint as its industry representative. Otulana, who joined Aradigm in 1997, previously served as a medical reviewer at the Center for Drug Evaluation & Research's pulmonary division. Aradigm's AERx pulmonary drug delivery platform recently completed Phase II studies with Novo Nordisk for an inhaled insulin formulation. A Phase III study could begin in early 2002, firm says...
General v. specific indications
DCRD initiative to allow general use labeling for electrophysiology catheters may also be applicable to other well established technologies. The division plans to allow cardiac ablation catheters to use a general indication for treatment of arrhythmias, rather than requiring PMA supplements for each individual application (1"The Gray Sheet," Jan. 8, 2001, p. 6). "We're taking a good hard look at some of those technologies that may be 10, 15 or 20 years old and have multiple singular indications associated where can we bring them together to have a more generic indication for use," Dillard says. Grouping indications, "so that we're only looking at one application as opposed to multiple applications," will serve to decrease the division's workload